

## DRUG NAME: Methotrexate

**SYNONYM(S):** amethopterin,<sup>1</sup> MTX

**COMMON TRADE NAME(S):**

**CLASSIFICATION:** antimetabolite

*Special pediatric considerations are noted when applicable, otherwise adult provisions apply.*

### MECHANISM OF ACTION:

Methotrexate is a folate antagonist.<sup>2</sup> Tetrahydrofolate is the active form of folic acid required for purine and thymidylate synthesis. Folic acid is reduced to tetrahydrofolate by dihydrofolate reductase (DHFR). The cytotoxicity of methotrexate results from three actions: inhibition of DHFR, inhibition of thymidylate, and alteration of the transport of reduced folates.<sup>3</sup> Inhibition of DHFR results in a deficiency of thymidylate and purines and therefore a decrease in DNA synthesis, repair and cellular replication.<sup>3</sup> The affinity of DHFR to methotrexate is far greater than its affinity for folic acid or dihydrofolic acid, therefore large doses of folic acid given simultaneously will not reverse the effects of methotrexate.<sup>2</sup> However, leucovorin calcium, a derivative of tetrahydrofolic acid, may block the effects of methotrexate if given shortly after the methotrexate since it does not require DHFR for activation.<sup>2</sup> Moderate ( $\geq 100$  mg/m<sup>2</sup>) to high-dose methotrexate ( $\geq 1000$  mg/m<sup>2</sup>)<sup>4</sup> plus leucovorin rescue is routinely used therapeutically in cancer treatment.<sup>3</sup> Methotrexate is most active against rapidly multiplying cells because the cytotoxic effects occur primarily during the S phase of the cell cycle.<sup>3</sup> Methotrexate also has immunosuppressive activity, possibly due to inhibition of lymphocyte multiplication.<sup>5</sup>

### PHARMACOKINETICS:

Interpatient variability	significant differences in time to peak concentration	
Oral Absorption	highly variable and dose dependent <sup>5</sup> ; 60% for doses up to 30 mg/m <sup>2</sup> ; significantly less for doses >80mg/m <sup>2</sup>	
	food delays absorption and reduces peak concentration	
	time to peak plasma concentration	1-2 h
Distribution	actively transported across cell membranes at serum concentrations < 0.1 $\mu$ mol/mL, mainly passive diffusion at higher concentration <sup>5</sup> ; widely distributed with highest concentration in kidneys, gallbladder, spleen, liver, and skin <sup>5</sup> ; also distributes into third space fluids <sup>5</sup>	
	cross blood brain barrier?	a ratio of 10-30:1 for CNS concentrations of methotrexate <sup>6</sup> ; higher CNS concentrations noted in patients with recent cranial irradiation and in patients with primary CNS lymphoma due to disruption of the blood-brain barrier
	volume of distribution	0.4-0.8 L/kg
	plasma protein binding	50%
Metabolism	<10%; hepatic and intracellular	
	active metabolite	methotrexate polyglutamates <sup>5</sup> and 7-hydroxy-methotrexate <sup>7</sup>
	inactive metabolite	4-amino-4-deoxy-N <sup>10</sup> -methylpteroic acid (DAMPA) <sup>8</sup>
Excretion	primarily renal via glomerular filtration and active tubular secretion	
	urine	80-90%

	feces	10% biliary
	terminal half life	3-10 h for doses < 30 mg/m <sup>2</sup> ; 8-15 h for higher doses <sup>5</sup>
	clearance	decreased at higher doses
Children <sup>8</sup>	more rapid elimination in urine; greater volume of distribution	

Adapted from standard reference<sup>2</sup> unless specified otherwise.

### USES:

#### **Primary uses:**

- \*Bladder cancer
- \*Breast cancer
- \*Gastric cancer
- \*Choriocarcinoma
- Gestational trophoblastic cancer<sup>11</sup>
- \*Head and neck cancer
- \*Leptomeningeal cancer
- \*Leukemia, acute lymphoblastic
- \*Lymphoma, Burkitt's
- \*Lymphoma, childhood
- \*Lymphoma, cutaneous T-cell (mycosis fungoides)
- \*Lymphoma, non-Hodgkin's
- \*Sarcoma, osteogenic
- Urothelial cancer<sup>12</sup>

#### **Other uses:**

- Leukemia, acute lymphocytic<sup>9</sup>
- Leukemia, acute promyelocytic<sup>9</sup>
- Sarcoma, soft tissue<sup>9</sup>
- Lymphoma, intraocular<sup>10</sup>

\*Health Canada approved indication

### SPECIAL PRECAUTIONS:

#### **Caution:**

- **Pleural effusions or ascites**<sup>3</sup>: Methotrexate exits slowly from third space compartments resulting in prolonged half-life and unexpected toxicity. In patients with significant third space accumulation, the fluid should be removed prior to treatment and methotrexate levels should be monitored.<sup>3</sup> If the fluid cannot be drained prior to therapy, a dose reduction is appropriate.<sup>13</sup>

**Special populations: Elderly patients** may be at increased risk for toxicity due to decreased hepatic and renal function, as well as decreased folate stores.<sup>3</sup> A dose reduction as well as monitoring for early signs of toxicities should be considered.<sup>3</sup>

**Carcinogenicity:** There are no controlled studies in humans. Evidence regarding increased risk of tumours is conflicting, complicating the assessment of carcinogenic potential. Malignant lymphomas have been reported in patients receiving low-dose methotrexate, but in some patients, they may regress without treatment following methotrexate withdrawal. Animal studies have been inconclusive. However, there is evidence that methotrexate causes chromosomal damage to animal somatic cells and human bone marrow cells; clinical significance is unknown.<sup>14</sup>

**Mutagenicity:** Clastogenic in mammalian *in vitro* and *in vivo* chromosome tests.<sup>5</sup>

**Fertility:** Methotrexate therapy may result in impairment of fertility, oligospermia, and menstrual dysfunction in humans, during and for a short period after cessation of therapy.<sup>14,15</sup>

**Pregnancy:** Methotrexate can cause fetal death, embryotoxicity, abortion, and teratogenic effects in humans. The optimal time interval between cessation of methotrexate treatment of either partner and pregnancy has not been established. Published intervals vary from 3 months to 1 year after treatment has ended.<sup>14,15</sup>


**Breastfeeding** is contraindicated as methotrexate has been detected in human breast milk.<sup>14,15</sup>

**Leucovorin rescue**<sup>4</sup> is required in some methotrexate regimens.

**Methotrexate dose:**

- >500 mg/m<sup>2</sup> requires leucovorin rescue.
- 100-500 mg/m<sup>2</sup> may require leucovorin rescue.

**Bleyer Nomogram:**



Reference: Bleyer WA. The clinical pharmacology of methotrexate – new applications of an old drug. Cancer 1978;41(1):36-51

Note: 0.05 micromol/L = 5 x 10<sup>-2</sup> micromoles/L

**Leucovorin dose PO/IV/IM (see Bleyer nomogram):**

- 10-25 mg/m<sup>2</sup> every 6 hours for approximately 8 to 10 doses, starting 24 hours after the start of methotrexate infusion.<sup>4,16-20</sup> (note: for leucovorin doses >25 mg administer IV).<sup>21</sup>
- Leucovorin dose modifications begin on day 3, if required, based on methotrexate levels taken that morning (i.e., level taken 36-48 hours following the start of the methotrexate infusion). Methotrexate levels are repeated every morning and leucovorin adjusted based on the graph to follow.<sup>16-18</sup>
- Continue until the methotrexate level is <0.05 to 0.1 micromol/L.<sup>22,23</sup> The change in threshold concentration from 0.05 microl/L (as per Bleyer nomogram) to 0.1 micromol/L is a result of worldwide changes in the immunoassay used to measure methotrexate serum levels. New laboratory methods have a higher limit of detection than previous methods and inaccuracies have been reported with methotrexate levels below 0.1 micromol/L.<sup>24</sup>

Note: Leucovorin doses >25 mg should be given IV<sup>21</sup>

## SIDE EFFECTS:

The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical practice. Adverse events are generally included if they

were reported in more than 1% of patients in the product monograph or pivotal trials, and/or determined to be clinically important.<sup>25</sup> When placebo-controlled trials are available, adverse events are included if the incidence is  $\geq$  5% higher in the treatment group.

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b><i>bold, italics</i></b>	
allergy/immunology	anaphylaxis (<1%)
	vasculitis (1-10%)
auditory/hearing	tinnitus
blood/bone marrow/ febrile neutropenia	anemia
	<b><i>neutropenia</i></b> : 1 <sup>st</sup> nadir 4-7 days with recovery in 7-13 days; 2 <sup>nd</sup> nadir 12-21 days with recovery in 15-20 days <sup>26</sup>
	<b><i>thrombocytopenia</i></b> : nadir 5-12 days with recovery in 15-27 days <sup>26</sup>
cardiovascular (general)	hypotension
	pericardial effusion
	pericarditis
constitutional symptoms	chills and fever (frequent) <sup>26</sup>
	fatigue (frequent) <sup>26</sup>
	malaise (1-10%)
	mood alteration; with low-dose methotrexate
dermatology/skin	<b><i>extravasation hazard</i></b> : none <sup>27</sup>
	acne
	alopecia (1-10%); usually reversible but may require several months <sup>26</sup>
	dermatitis
	erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, toxic epidermis necrolysis <sup>3</sup>
	folliculitis
	furunculosis
	photosensitivity (1-10%)
	pigmentary changes (1-10%)
	pruritus
	rash (1-10%); on extremities <sup>26</sup>
	reddening of skin (>10%)
	skin necrosis <sup>3</sup>
	telangiectasia
urticaria	
endocrine	diabetes (1-10%)
gastrointestinal	<b><i>emetogenic potential</i></b> <sup>28</sup> : dose-related: moderate (high-moderate for >1000 mg/m <sup>2</sup> ; low-moderate for 250-1000 mg/m <sup>2</sup> ); low for $\leq$ 250 mg/m <sup>2</sup> to >50 mg/m <sup>2</sup> ; rare for $\leq$ 50 mg/m <sup>2</sup>
	abdominal discomfort

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b><i>bold, italics</i></b>	
	anorexia (>10%)
	diarrhea (>10%)
	gingivitis (>10%)
	glossitis (>10%)
	nausea; dose-related
	perforation (>10%) <sup>4</sup>
	pharyngitis
	<b><i>stomatitis</i></b> (>10%)
	<b><i>vomiting</i></b> ; dose-related
hemorrhage	ecchymoses, petechiae
	hematemesis <sup>5</sup>
	hematuria
	melena <sup>5</sup>
hepatobiliary/pancreas	pancreatitis
hepatic	<b><i>hepatotoxicity</i></b> (1-10%)
metabolic/laboratory	<b><i>azotemia</i></b> ; more common with high-dose methotrexate than with low-dose <sup>25</sup>
	hyperuricemia (>10%)
	liver function tests, elevated <sup>5</sup> ; usually transient, asymptomatic and return to normal within 10 to 14 days <sup>25</sup>
musculoskeletal	arthralgia/myalgia (1-10%)
	hemiparesis
	osteoporosis, fractures; with high-dose methotrexate <sup>26</sup>
	osteonecrosis
	soft tissue necrosis
neurology	<b><i>neurotoxicities</i></b> (>10%); with intrathecal administration or high-dose methotrexate
	cognitive dysfunction, mild transient (<1%); with low-dose methotrexate <sup>26</sup>
	cranial sensations; with low-dose methotrexate
	dizziness (1-10%)
	seizure (1-10%)
ocular/visual	blurred vision (1-10%)
	conjunctivitis
	eye discomfort
	severe visual changes
pain	headache <sup>26</sup>

ORGAN SITE	SIDE EFFECT
Clinically important side effects are in <b>bold, italics</b>	
pulmonary	<b>pulmonary toxicity</b> (2-8%) <sup>29</sup> ; can occur with all doses of methotrexate, although more often with chronic low-dose <sup>25</sup>
renal/genitourinary	<b>renal dysfunction</b> (1-10%); with high-dose methotrexate
secondary malignancy	lymphomas; may regress following withdrawal of methotrexate <sup>3</sup>
sexual/reproductive function	<b>abortifacient, fetal defects</b> <sup>26</sup>
	gynecomastia
	loss of libido/impotence
	menstrual dysfunction
	oogenesis, interference with
	spermatogenesis, interference with
syndromes	<b>acute neurologic syndrome</b> (<1%); with high-dose methotrexate
	<b>tumour lysis syndrome</b> ; especially when given for systemic Burkitt's lymphoma <sup>25</sup>
vascular	cerebral thrombosis
	deep vein thrombosis
	pulmonary embolism
	retinal vein thrombosis

Adapted from standard references<sup>2,30</sup> unless specified otherwise.

**Glucarpidase** (*carboxypeptidase-G2*, CPDG2, VORAXAZE®<sup>31,32</sup>) is a recombinant bacterial enzyme that inactivates extracellular methotrexate to 2,4-diamino-N<sup>10</sup>-methylpteroic acid [DAMPA].<sup>31</sup> Glucarpidase can rapidly lower serum methotrexate levels by >95% within 15 minutes of administration.<sup>33</sup> Cellular uptake of glucarpidase is increased when it is given with leucovorin. However, leucovorin is a weak substrate for glucarpidase and may compete with methotrexate for binding. Therefore, administration time of leucovorin and glucarpidase should be separated.<sup>31</sup> Also, leucovorin should be continued after administration of glucarpidase, which may deactivate the active metabolite of leucovorin<sup>34,35</sup>. Glucarpidase can be used to treat patients at risk for methotrexate toxicity secondary to delayed elimination<sup>31</sup> and is available through the Health Canada Special Access Programme:

- Glucarpidase 50 units/kg IV over 5 minutes<sup>31</sup>
  - For methotrexate level >100 micromol/L, may give second dose of glucarpidase 48 hours after administration of first dose.<sup>36</sup>
- High-dose leucovorin (eg, 1000 mg/m<sup>2</sup> IV every 6 hours) should be given prior to the receipt and administration of glucarpidase.<sup>36</sup>
  - Leucovorin should be given at least 2-4 hours before or after administration of glucarpidase.<sup>31</sup>
  - After administration of glucarpidase, leucovorin should be continued at a high dose of 250 mg/m<sup>2</sup> IV every 6 hours for a total of 48 hours; after that time, leucovorin rescue should be modified based on methotrexate levels and clinical signs of toxicity.<sup>36</sup>
  - Note that following glucarpidase administration, methotrexate level based on standard clinical immunoassay methods may be artificially high due to interference from high levels of DAMPA.<sup>31</sup>

Methotrexate-induced **hepatotoxicity** can be seen with both high and low-dose methotrexate, and can be life-threatening.<sup>26</sup> Increased serum aminotransferases (14%) and less commonly hyperbilirubinemia is seen more often in high-dose methotrexate.<sup>8</sup> The liver enzymes can increase with each cycle, and usually return to pre-treatment levels once methotrexate has been discontinued for 1 month.<sup>37</sup> Cirrhosis and fibrosis are more often seen with

chronic low-dose methotrexate.<sup>8,37</sup> See Dosing guidelines for hepatic failure. Patients should be warned to avoid alcohol, prescription medications or herbal supplements that may increase risk of hepatotoxicity.<sup>25</sup>

**Hyperuricemia** may result from cell lysis by cytotoxic chemotherapy and may lead to electrolyte disturbances or acute renal failure.<sup>38</sup> It is most likely with highly proliferative tumours of massive burden, such as leukemias, high-grade lymphomas, and myeloproliferative diseases. The risk may be increased in patients with pre-existing renal dysfunction, especially ureteral obstruction. Suggested prophylactic treatment for high-risk patients<sup>39</sup>:

- aggressive hydration: 3 L/m<sup>2</sup>/24 hr with target urine output >100 ml/h
- if possible, discontinue drugs that cause hyperuricemia (e.g., thiazide diuretics) or acidic urine (e.g., salicylates)
- monitor electrolytes, calcium, phosphate, renal function, LDH, and uric acid q6h x 24-48 hours
- replace electrolytes as required
- allopurinol 600 mg po initially, then 300 mg po q6h x6 doses, then 300 mg po daily x 5-7 days

Urine should be alkalinized only if the uric acid level is elevated, using sodium bicarbonate IV or PO titrated to maintain urine pH greater than 7. Rasburicase (FASTURTEC®) is a novel uricolytic agent that catalyzes the oxidation of uric acid to a water-soluble metabolite, removing the need for alkalinization of the urine.<sup>40</sup> It may be used for treatment or prophylaxis of hyperuricemia; however, its place in therapy has not yet been established. Aluminum hydroxide (e.g., AMPHOGEL®) may be added orally if phosphate becomes elevated. If aluminium hydroxide has been added, discontinue sodium bicarbonate.<sup>41</sup>

**Neurologic complications**<sup>30</sup>: Methotrexate-induced neurotoxicities can be seen with intrathecal injection of methotrexate and with high-dose methotrexate.<sup>4</sup> The neurotoxicities may be due to the accumulation of adenosine resulting from the inhibition of purine synthesis.<sup>26</sup>

#### *For Intrathecal (IT) administration*

- Aseptic meningitis<sup>30</sup>: This is the most common toxicity seen with IT administration (10%); includes headache, neck rigidity, back pain, nausea, vomiting, fever, and lethargy. Aseptic meningitis can begin 2-4 hours after the drug is injected, and can last 12-72 hours. There is usually no treatment required; the risk of developing this can be decreased by the administration of IT hydrocortisone, or oral corticosteroids. Patients may be rechallenged.
- Transverse myelopathy<sup>30</sup>: This is much less common<sup>30</sup>; includes isolated spinal cord dysfunction over hours or days. Transverse myelopathy can begin between 30 minutes and 48 hours after treatment. This is more common with concurrent radiotherapy or frequent IT injections of methotrexate. Recovery from this condition is variable. Patients are not rechallenged.
- Leukoencephalopathy<sup>30</sup>: This can be a delayed complication and is more common in patients receiving whole brain radiotherapy or previous IV methotrexate. Symptoms include confusion, irritability, somnolence, ataxia, dementia, and occasionally seizures and coma.<sup>5</sup>
- Encephalopathy, seizures, neurologic deficits, lumbosacral radiculopathy, neurogenic pulmonary edema, and sudden death can rarely occur.<sup>30</sup>

#### *For high-dose methotrexate ( $\geq 1000$ mg/m<sup>2</sup>)*

- Acute neurotoxicity<sup>30</sup>: includes somnolence, confusion, and seizures within 24 hours of treatment. These usually resolve spontaneously; rechallenge is possible.
- Subacute neurotoxicity<sup>30</sup>: seen with weekly or every two week administration. “Stroke-like” syndrome, including transient neurologic deficits, confusion, and seizures. Occurring about 6 days after drug administration, lasting from 15 minutes to 72 hours and then resolving. Rechallenge is possible.

Leukoencephalopathy: refer to “for IT administration” above.

Methotrexate-induced **pulmonary toxicity** can be seen with both high and low-dose methotrexate, and can be life-threatening.<sup>26</sup> Pulmonary toxicity can be either symptomatic or asymptomatic and can be caused by inflammation, infection or neoplasia.<sup>26</sup>

- Inflammatory lung disease: most common here is hypersensitivity pneumonitis.<sup>29</sup>
  - Pulmonary infections: opportunistic infections due to compromised immune system.<sup>29</sup>
  - Pulmonary lymphoma: Non-Hodgkin’s (B cell) lymphoma which regresses after discontinuation of methotrexate.<sup>29</sup>
- Methotrexate-induced pulmonary toxicity can be acute, subacute, or chronic.<sup>29</sup> Patients who experience pulmonary toxicity will often develop this within the first year of methotrexate therapy, but it can occur much earlier or much later.<sup>29</sup> Subacute toxicity is the most common and includes dyspnea, non-productive cough, fever, crackles, cyanosis, pulmonary fibrosis, pleural effusions.<sup>29</sup> Treatment includes discontinuing methotrexate and initiating

corticosteroid therapy.<sup>29</sup> Improvement can occur within days of stopping methotrexate; rechallenging with the drug is not recommended.<sup>29</sup>

High-dose methotrexate-induced **renal failure** is a medical emergency because methotrexate is mainly eliminated by the kidneys.<sup>42</sup> Renal damage is due to precipitation of methotrexate in the tubules and to tubule injury. Drug precipitation can often be prevented by hydration and alkalization of the urine.<sup>8</sup> Hydration produces a high urine output and lowers the concentration of methotrexate in the tubular fluid; alkalization of the urine increases the solubility of methotrexate. During the recovery period sustained methotrexate levels may result in substantial bone marrow and gastrointestinal toxicity.<sup>25</sup> Management should include continued monitoring of methotrexate levels, administration of leucovorin (see leucovorin rescue) and alkalized intravenous fluids until plasma levels fall below 0.05 micromol/L.<sup>25</sup>

**INTERACTIONS:**

AGENT	EFFECT	MECHANISM	MANAGEMENT
acitretin <sup>4,43</sup>	delayed, major, suspected; increased methotrexate hepatic toxicity	unknown	avoid concurrent use
alcohol <sup>4</sup>	enhanced hepatotoxicity	additive	limit or avoid alcohol intake during therapy
aminoglycosides, oral <sup>43</sup>	delayed, moderate, possible; decreased methotrexate levels	decreased GI absorption of methotrexate	consider parenteral use of methotrexate
amiodarone <sup>43</sup>	delayed, major, possible; increased methotrexate levels	unknown	consider monitoring for methotrexate toxicity
asparaginase <sup>44</sup>	decreased effect of methotrexate when asparaginase is given immediately prior to or with methotrexate; enhanced effect of methotrexate when asparaginase is given after methotrexate	suppression of asparagine concentrations	give asparaginase 9-10 days before methotrexate or shortly after methotrexate
azathioprine <sup>43</sup>	delayed, moderate, possible; increased azathioprine levels	decreased metabolism of azathioprine	primarily a concern with high-dose methotrexate; dose reduction may be considered for azathioprine
bile acid sequestrants (e.g., cholestyramine, colestipol) <sup>45</sup>	may decrease methotrexate levels	decreased absorption of methotrexate <sup>45</sup>	separate the administration of these drugs by 2 or more hours
caffeine <sup>43</sup>	delayed, moderate, possible; decreased methotrexate antirheumatic effect	unknown	monitor clinical response; consider reduction in caffeine intake if needed
carboxypeptidase G2 (CPDG2) <sup>46</sup>	decreased toxicity of methotrexate	rapidly metabolizes methotrexate	may be used to rapidly lower serum methotrexate
chloroquine <sup>43</sup>	delayed, minor, possible; decreased methotrexate antirheumatic effect	unknown	monitor clinical response; consider increase in methotrexate dose



AGENT	EFFECT	MECHANISM	MANAGEMENT
corticosteroids <sup>4</sup>	may decrease methotrexate levels in leukemia cells	may decrease the uptake of methotrexate into leukemia cells	separate the administration of these drugs by 12 hours; note that dexamethasone does not appear to affect methotrexate uptake into cells
cyclosporine <sup>4</sup>	may increase both methotrexate and cyclosporine toxicity	unknown <sup>47</sup>	monitor for both cyclosporine and methotrexate toxicity <sup>47</sup>
cytarabine <sup>4</sup>	methotrexate, when administered prior to cytarabine, may enhance the efficacy and toxicity of cytarabine	unknown	some protocols are designed to take advantage of this effect; monitor toxicity
digoxin <sup>43</sup>	delayed, moderate, suspected; decreased digoxin levels	decreased GI absorption of digoxin	monitor for digoxin pharmacologic effects
doxycycline <sup>43</sup>	delayed, major, possible; increased methotrexate levels	unknown	monitor for methotrexate toxicity
haloperidol <sup>43</sup>	delayed, moderate, possible; increased methotrexate dermatological toxicity	unknown	monitor for methotrexate toxicity
hydroxychloroquine <sup>43</sup>	delayed, minor, possible; decreased methotrexate antirheumatic effect	unknown	monitor clinical response; consider increase in methotrexate dose
leucovorin	decreased toxicity of methotrexate	leucovorin "rescues" normal cells from toxic effects of methotrexate	administer leucovorin after methotrexate if required
mercaptopurine <sup>4,43</sup>	delayed, moderate, possible; increased mercaptopurine levels	decreased metabolism of mercaptopurine	primarily a concern with high-dose methotrexate; dose reduction may be considered for mercaptopurine
NSAIDs (e.g., diclofenac, ibuprofen, naproxen) <sup>4,43</sup>	delayed, major, suspected; increased methotrexate levels	reduced renal clearance of methotrexate	primarily a concern with high-dose methotrexate; monitor methotrexate levels i.e., longer leucovorin rescue; note that risk may be lower with selective COX-2 inhibitors (e.g., celecoxib)
omeprazole, pantoprazole, esomeprazole, other proton pump inhibitors (PPI) <sup>7,48-51</sup>	increased methotrexate and 7-hydroxy-methotrexate levels, leading to increased methotrexate toxicity	mechanism unclear; possibly reduced renal clearance of methotrexate and 7-hydroxy-methotrexate	monitor for methotrexate toxicity; for high-dose methotrexate, consider discontinuing PPI one day prior to methotrexate; consider an H2 antagonist (e.g., ranitidine) instead of PPI

AGENT	EFFECT	MECHANISM	MANAGEMENT
penicillins (e.g., amoxicillin, piperacillin, ticarcillin) <sup>4,43</sup>	delayed, major, suspected; increased methotrexate levels	competitive inhibition of renal tubular secretion of methotrexate	primarily a concern with high doses of penicillins and high-dose methotrexate; monitor for methotrexate toxicity longer leucovorin rescue
phenytoin <sup>43</sup>	delayed, moderate, suspected; decrease phenytoin levels	decreased absorption or increased metabolism of phenytoin	monitor for phenytoin levels
probenecid <sup>4,43</sup>	rapid, major, probable; increased methotrexate levels	decreased renal excretion of methotrexate.	primarily a concern with high-dose methotrexate; monitor methotrexate levels i.e., longer leucovorin rescue
procarbazine <sup>43</sup>	delayed, major, possible; increased methotrexate renal toxicity	unknown	consider allowing an interval of $\geq 72$ h between the administration of the final dose of procarbazine and the initiation of a high-dose methotrexate infusion
salicylates (e.g., ASA) <sup>4,43,52,53</sup>	rapid, major, suspected; increased methotrexate levels	decreased renal clearance and plasma protein binding of methotrexate	salicylate doses used for prophylaxis of cardiovascular events are not likely to be a concern; consider monitoring methotrexate levels
sulfonamides (e.g., co-trimoxazole, sulfamethoxazole, sulfisoxazole) <sup>4,43,52,53</sup>	delayed, major, suspected; increased methotrexate levels	decreased protein binding and renal clearance of methotrexate; methotrexate may induce folate deficiency, which can develop into acute megaloblastic anemia upon administration of timethoprin-sulfamethoxazole	primarily a concern with high-dose methotrexate; monitor methotrexate levels i.e., longer leucovorin rescue
tetracycline <sup>43</sup>	delayed, major, possible; increased methotrexate levels	unknown	monitor for methotrexate toxicity
theophylline <sup>4</sup>	methotrexate may increase theophylline levels	decreased clearance of theophylline <sup>5</sup>	monitor for theophylline levels <sup>5</sup>
thiazides <sup>43</sup>	delayed, moderate, possible; increased methotrexate induced myelosuppression	unknown	consider alternative antihypertensive therapy
trimethoprim <sup>43</sup>	delayed, major, suspected; increased methotrexate toxicities	both drugs are folate antagonists and may have synergistic effect on folate metabolism	monitor for methotrexate toxicity

AGENT	EFFECT	MECHANISM	MANAGEMENT
urine alkalizers (e.g., potassium acetate, potassium citrate, sodium acetate, sodium bicarbonate, sodium citrate, sodium lactate)	rapid, minor, possible; decreased methotrexate levels	increased renal excretion of methotrexate	no clinical intervention required

## SUPPLY AND STORAGE:

### Oral:

Accord Healthcare Inc.,<sup>54</sup> Apotex Inc.,<sup>55</sup> and Pharmascience Inc.<sup>56</sup> supplies methotrexate as 2.5 mg tablets. Tablets contain lactose. Store at room temperature and protect from light.

Pfizer Canada ULC supplies methotrexate as 10 mg tablets. Tablets contain lactose. Store at room temperature and protect from light.<sup>57</sup>

### Injection:

Pfizer Canada ULC supplies methotrexate as 20 mg/2 mL and 50 mg/2 mL ready-to-use, single use (preservative free) vials; as 500 mg/20 mL, 1 g/40 mL, and 2.5 g/100 mL ready-to-use, multi-dose (preservative free) vials; and as 50 mg/2 mL and 500 mg/20 mL ready-to-use, multi-dose (with preservative) vials. Store at room temperature. Protect from light.<sup>14</sup>

Accord Healthcare Inc. supplies methotrexate as 50 mg/2 mL, 500 mg/20 mL, and 1 g/40 mL ready-to-use, single use (preservative free) vials and 50 mg/2 mL and 500 mg/20 mL ready-to-use, multi-dose (with preservative) vials. Store at room temperature. Protect from light.<sup>15</sup>

**For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.**

## SOLUTION PREPARATION AND COMPATIBILITY:

**For basic information on the current brand used at BC Cancer, see [Chemotherapy Preparation and Stability Chart](#) in Appendix.**

### Additional information:

- methotrexate is sparingly soluble in acidic conditions and precipitation may occur<sup>2</sup>
- for intraocular use (i.e., intravitreal injection), preservative free methotrexate is preferred<sup>58</sup>

**Compatibility:** consult detailed reference

## PARENTERAL ADMINISTRATION:

BC Cancer administration guideline noted in **bold, italics**

Subcutaneous	can be used <sup>8</sup>
<b><i>Intramuscular</i></b>	<b><i>inject into a suitable muscle</i></b> <sup>11,14,59,60</sup>
<b><i>Direct intravenous</i></b>	IV push <sup>48,61</sup>
<b><i>Intermittent infusion*</i></b>	<b><i>over 20 min to 24 h</i></b> <sup>30</sup>
<b><i>Continuous infusion*</i></b>	<b><i>over 24-42 h</i></b> <sup>30</sup>
Intraperitoneal	no information found

BC Cancer administration guideline noted in <b>bold, italics</b>	
Intrapleural	no information found
<b>Intrathecal†</b>	<b>dilute in small volume (5-10 mL)<sup>62</sup> preservative-free NS to a concentration of 1-2 mg/mL<sup>5,63</sup></b> ; some clinicians use higher concentrations <sup>63</sup>
Intra-arterial	can be used <sup>2</sup>
Intravesical	no information found
Intraocular <sup>10,64,65</sup>	has been used; give 0.1 mL as intravitreal injection in the affected eye

\*High-dose methotrexate requires preservative-free methotrexate and leucovorin rescue.<sup>66</sup>

†Intrathecal methotrexate requires preservative-free methotrexate. See [BC Cancer Policy III-50 Administration of High Alert Medications by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir](#).

### DOSAGE GUIDELINES:

Refer to protocol by which patient is being treated. Numerous dosing schedules exist and depend on disease, response and concomitant therapy. Guidelines for dosing also include consideration of absolute neutrophil count (ANC). Dosage may be reduced, delayed or discontinued in patients with bone marrow depression due to cytotoxic/radiation therapy or with other toxicities.

#### Adults:

BC Cancer usual dose noted in **bold, italics**

Oral:	Cycle Length: <b>1 week<sup>67</sup>:</b>	<b>15-25 mg/m<sup>2</sup> PO for one dose on day 1 and then day 3 or 4</b> (total dose per cycle 30-50 mg/m <sup>2</sup> )
	<b>4 weeks<sup>68-71</sup></b>	<b>2.5 mg PO once or twice a day for 2 consecutive days starting on day 1 and 2 of each week*</b> (total dose per cycle 20-40 mg)  (*two non-consecutive days of the week have also been used for metronomic or low-dose dosing) <sup>71,72</sup>
Intravenous:	<b>1 week<sup>67</sup>:</b>	<b>40 mg/m<sup>2</sup> IV for one dose on day 1</b> (total dose per cycle 40 mg/m <sup>2</sup> )
	<b>1-3 weeks<sup>73</sup>:</b>	<b>30-60 mg/m<sup>2</sup> IV for one dose on day 1</b> (total dose per cycle 30-60 mg/m <sup>2</sup> )
	<b>1-4 weeks<sup>74,75</sup>:</b>	<b>1000-12000 mg/m<sup>2</sup> IV over 4 hours for one dose on day 1</b> (total dose per cycle 1000-12000 mg/m <sup>2</sup> ) requires leucovorin rescue (see <i>Special Precautions</i> )
	<b>2 weeks<sup>59,60</sup>:</b>	<b>0.4 mg/kg/day IV for one dose on days 1 to 5 max 25 mg/day</b> (total dose per cycle 2 mg/kg; max 250 mg)
	<b>2 weeks<sup>76</sup>:</b>	<b>25 mg/m<sup>2</sup> IV for one dose on day 1</b> (total dose per cycle 25 mg/m <sup>2</sup> )

BC Cancer usual dose noted in **bold, italics**

	Cycle Length:	
	<b>2 weeks</b> <sup>12,77,78:</sup> :	<b>30 mg/m<sup>2</sup> IV for one dose on day 1</b> (total dose per cycle 30 mg/m <sup>2</sup> )
	<b>2 weeks</b> <sup>20:</sup> :	<b>100 mg/m<sup>2</sup> IV for one dose and 300 mg/m<sup>2</sup> IV over 4 hours for one dose both on day 1</b> (total dose per cycle 400 mg/m <sup>2</sup> ) requires leucovorin rescue (see <i>Special Precautions</i> )
	<b>2 weeks</b> <sup>19:</sup> :	<b>100 mg/m<sup>2</sup> IV for one dose and 300 mg/m<sup>2</sup> IV over 4 hours for one dose both on day 8</b> (total dose per cycle 400 mg/m <sup>2</sup> ) requires leucovorin rescue (see <i>Special Precautions</i> )
	<b>2 weeks</b> <sup>19:</sup> :	<b>1000 mg/m<sup>2</sup> IV over 24 hours for one dose on day 8</b> (total dose per cycle 1000 mg/m <sup>2</sup> ) requires leucovorin rescue (see <i>Special Precautions</i> )
	<b>3 weeks</b> <sup>18:</sup> :	<b>3000 mg/m<sup>2</sup> IV over 4 hours for one dose on day 10</b> (total dose per cycle 3000 mg/m <sup>2</sup> ) requires leucovorin rescue (see <i>Special Precautions</i> )
	<b>4 weeks</b> <sup>79,80:</sup> :	<b>40 mg/m<sup>2</sup> IV for one dose on days 1 and 8</b> (total dose per cycle 80 mg/m <sup>2</sup> )
	<b>4 weeks</b> <sup>81:</sup> :	<b>30 mg/m<sup>2</sup> IV for one dose on days 1 and 15 and 22</b> (total dose per cycle 90 mg/m <sup>2</sup> )
<i>Intramuscular:</i>	<b>2 weeks</b> <sup>11,59,60:</sup> :	<b>50 mg IM for one dose on days 1, 3, 5, and 7 OR days 1, 3, 5, and 8</b> (total dose per cycle 200 mg)
	2 weeks <sup>60:</sup> :	1 mg/kg IM for one dose on days 1, 3, 5, and 7 OR days 1, 3, 5, and 8 (total dose per cycle 4 mg/kg)
	weekly <sup>14:</sup> :	15-30 mg IM for one dose on days 1-5 (total dose per cycle 75-150 mg)
	weekly <sup>14:</sup> :	50 mg IM for one dose on day 1 OR 25 mg IM for one dose twice weekly (total dose per cycle 50 mg)
<i>Intrathecal:</i>	n/a	<b>12 mg IT for one dose once or twice weekly</b> <sup>82,83</sup> (maximum two IT injections per week)
	n/a	<b>12-12.5 mg IT as part of combination therapy once weekly</b> <sup>18,19</sup>

BC Cancer usual dose noted in ***bold, italics***

**Intraocular:** Cycle Length: **2-4 weeks**<sup>10,64,65;</sup> **400 mcg/0.1 mL by intravitreal injection in the affected eye for one dose**

**Concurrent radiation:** increased risk of soft tissue necrosis and osteonecrosis<sup>2</sup>

**Dosage in myelosuppression:** modify according to protocol by which patient is being treated; if no guidelines available, refer to Appendix "Dosage Modification for Myelosuppression"

**Dosage in renal failure:**

Suggested dose modifications<sup>84:</sup>

Creatinine clearance (mL/min)	Methotrexate dose
61-80	75%
51-60	70%
10-50	30-50%
<10	avoid

$$\text{Calculated creatinine clearance} = \frac{N^* \times (140 - \text{Age}) \times \text{weight (kg)}}{\text{serum creatinine in micromol/L}}$$

\* For males N = 1.23; for females N=1.04

OR alternately, for creatinine clearance less than 100 mL/min, reduce methotrexate dose proportionately to the reduction in creatinine clearance:<sup>16,17,85,86</sup>

e.g., CrCl ≥100 mL/min, give 100% of dose

CrCl = 85 mL/min, give 85% of dose

CrCl = 60 mL/min, give 60% of dose

**Metronomic or low-dose dosing:**

Suggested dose modifications:<sup>68,69,72</sup>

Creatinine clearance (mL/min)	Methotrexate dose
>30	100%
15-30	50%
<15	avoid

$$\text{Calculated creatinine clearance} = \frac{N^* \times (140 - \text{Age}) \times \text{weight (kg)}}{\text{serum creatinine in micromol/L}}$$

\* For males N = 1.23; for females N=1.04

**Dosage in hepatic failure:**

Suggested dose modifications<sup>84,87</sup>

Bilirubin (micromol/L)	or	AST (units/L)	Dose
50-85		3 x ULN	75 %
>85		-	avoid

**Dosage in dialysis<sup>88:</sup>**

hemodialysis: 50% dose

chronic ambulatory peritoneal dialysis (CAPD): no information found

continuous renal replacement therapy (CRRT): 30-50% dose

**Children:**

	Cycle Length:	
<i>Oral, Intramuscular, Subcutaneous</i> <sup>8</sup> :	1-2 weeks:	7.5-30 mg/m <sup>2</sup>
<i>Intravenous</i> <sup>8</sup> : <i>bolus or continuous infusion (6-24 h)</i>	n/a	10-33,000 mg/m <sup>2</sup> *
		*Doses above 100 to 300 mg/m <sup>2</sup> , which are usually administered by continuous infusion, must be followed by leucovorin rescue. <sup>8</sup>
<i>Intrathecal</i> <sup>8</sup> :	n/a	6 mg (age <1 yr) 8 mg (age 1 yr) 10 mg (age 2 yr) 12 mg (age ≥3 yr)

**REFERENCES:**

1. Mayne Pharma Canada Inc. LEUCOVORIN CALCIUM® Injection product monograph. Montreal, Quebec; 2003
2. Mayne Pharma (Canada) Inc. Methotrexate injection product monograph. Montreal, Quebec; 6 Dec 2003
3. Mayne Pharma. Apo-methotrexate tablet product monograph. Montreal, Quebec; 2003
4. Rose BD editor. Methotrexate. (accessed 5 April 2006). Waltham, Massachusetts: UpToDate®; 2006
5. McEvoy GK, editor. AHFS 2006 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc.; . p. 1137-1145
6. Qin D, Ma J, Xiao J, et al. Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents. *Am J Clin Oncol* 1997;20(3):263-5
7. Joerger M, Huitema ADR, van den Bongard, H. J. G. D., et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. *Br J Clin Pharmacol* 2005;62(1):71-80
8. Pizzo P, Poplack D. Principles and Practice of Pediatric Oncology. 4th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2002
9. Lexi-Drugs® - Lexicomp Online (database on the Internet). Methotrexate. Wolters Kluwer Clinical Drug Information Inc., Available at: <http://online.lexi.com>. Accessed Aug 18, 2022
10. Benner JD, Dao D, Butler JW, et al. Intravitreal methotrexate for the treatment of proliferative vitreoretinopathy. *BMJ Open Ophthalmol* 2019;4(1):1-5
11. Sita-Lumsden A, Short D, Lindsay I, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009. *Br J Cancer* 2012;107(11):1810-1814
12. Choueiri TK, Jacobus S, Bellmunt J, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin With pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. *J Clin Oncol* 2014;32(18):1889-1894
13. Perry CP. Hepatotoxicity of chemotherapy. In *UpToDate* 14.3; Rose, Burton D. (Ed);, 2006. Available at: [www.uptodate.com](http://www.uptodate.com)
14. Pfizer Canada-ULC. Methotrexate injection product monograph. Kirkland, Québec; July 8, 2019
15. Accord Healthcare Inc. Methotrexate injection product monograph. Kirkland, Québec; October 30, 2019
16. BC Cancer Agency Lymphoma Tumour Group. (LYHDMTXR) BCCA Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate. Vancouver, British Columbia: BC Cancer Agency; 2004
17. BC Cancer Agency Lymphoma Tumour Group. (LYHDMTXP) BCCA Protocol Summary for Treatment of Leptomeningeal Lymphoma with High Dose Methotrexate. Vancouver, British Columbia: BC Cancer Agency; 2004
18. BC Cancer Agency Lymphoma Tumour Group. (LYSNCC) BCCA Protocol Summary for Treatment of Burkitt Lymphoma with Cyclophosphamide and Methotrexate. Vancouver, British Columbia: BC Cancer Agency; 2004
19. BC Cancer Agency Gynecologic Oncology Tumour Group. (GOTDHR) BCCA Protocol Summary for High Risk Gestational Trophoblastic Cancer (GO9130) "MACE" using Cisplatin, Etoposide, Actinomycin D, Methotrexate, and Leucovorin. Vancouver, British Columbia: BC Cancer Agency; 2005
20. BC Cancer Agency Gynecologic Oncology Tumour Group. (GOTDLR) BCCA Protocol Summary for Low Risk Gestational Trophoblastic Cancer using Dactinomycin and Methotrexate. Vancouver, British Columbia: BC Cancer Agency; 2003
21. Wyeth Canada. Lederle LEUCOVORIN® calcium folinate tablets Product Monograph. Montreal, Quebec; 2004
22. LaCasce AS. Therapeutic use and toxicity of high-dose methotrexate. In: 2017 UpToDate®; Basow, Denise S. (Ed); updated 2Nov2016; accessed 3Apr2017. Waltham, Massachusetts: UpToDate®; Available at [www.uptodate.com](http://www.uptodate.com); 2016
23. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. *Cancer* 1978;41(1):36-51



24. BC Cancer Agency Provincial Systemic Therapy Program. Systemic Therapy Update: Revised Methotrexate Levels for Initiating Oral Leucovorin (LYCODOXMR, LYHDMRP, LYHDMTXP, LYHDMTXR, MOHDMTX). 16(1) ed. Vancouver, British Columbia: BC Cancer Agency; January 2013
25. Tamara Shenkier MD. Medical Oncologist, BC Cancer Agency. Personal communication. June 2006
26. Kremer JM. Major side effects of methotrexate. UpToDate, 2006. Available at: [www.uptodate.com](http://www.uptodate.com). Accessed 8 May, 2006
27. BC Cancer Provincial Systemic Therapy Program. Provincial Systemic Therapy Program Policy III-20: Prevention and Management of Extravasation of Chemotherapy. Vancouver, British Columbia: BC Cancer; March 1 2021
28. BC Cancer. (SCNAUSEA) Guidelines for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults. Vancouver, British Columbia: BC Cancer; 1 July 2020
29. Balk RA. Methotrexate-induced lung injury. UpToDate, 2006. Available at: [www.uptodate.com](http://www.uptodate.com). Accessed 8 May, 2006
30. Wen PY, Plotkin SR. Neurologic complications of cancer chemotherapy. UpToDate, 2006. Available at: [www.uptodate.com](http://www.uptodate.com). Accessed 27 April, 2006
31. Protherics Inc. VORAXAZE® (glucarpidase; carboxypeptidase G2) product monograph. 2005
32. BTG International Inc. VORAXAZE® prescribing information. Brentwood, Tennessee USA; 03/ 2013
33. Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. *Cancer* 2004;100(10):2222-32
34. National Institute for Occupational Safety and Health, (NIOSH). Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. Cincinnati, Ohio: NIOSH - Publications Dissemination; September 2004. p. 31-40
35. National Institute for Occupational Safety and Health, (NIOSH). Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. Cincinnati, Ohio: NIOSH - Publications Dissemination; 25 March 2004. p. 71-83
36. Cancer Therapy Evaluation Program. Special Exception Protocol for the use of carboxypeptidase-G2 for MTX toxicity. Rockville, MD: National Cancer Institute; 3 June 2004
37. Kremer JM. Methotrexate-induced hepatotoxicity. UpToDate, 2006. Available at: [www.uptodate.com](http://www.uptodate.com). Accessed 8 May, 2006
38. DeVita VT, Hellman S, Rosenberg SA. *Cancer Principles & Practice of Oncology*. 6th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2001. p. 2640
39. Leukemia/Bone Marrow Transplant Program of British Columbia. *Leukemia/BMT Manual*. 4th ed. Vancouver, British Columbia: Vancouver Hospital and Health Sciences Centre / BC Cancer Agency; 2003. p. 27
40. Sanofi-Synthelabo. FASTURTEC® product information. Markham, Ontario; . 2004
41. Leukemia/Bone Marrow Transplant Program of British Columbia. *Leukemia/BMT Manual*. E-Edition ed. Vancouver, British Columbia: Vancouver Hospital and Health Sciences Centre / BC Cancer Agency; 2010. p. 93-94
42. Widemann BC, Hetherington ML, Murphy RF, et al. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. *Cancer* 1995;76(3):521-6
43. Wickersham R, Novak K, Schweain S editors. *Drug Facts and Comparisons*. St. Louis, Missouri: Wolters Kluwer Health, Inc; 2005
44. McEvoy GK. AHFS 2004 Drug Information. Bethesda, Maryland: American Society of Health-System Pharmacists, Inc.; 2006. p. 932-1168
45. Rose BD editor. *Methotrexate/ Bile Acid Sequestrants*. (accessed 26 April 2006). Waltham, Massachusetts: UpToDate®; 2006
46. Rose BD editor. *Crystal-induced acute renal failure*. UpToDate ed. Waltham, Massachusetts: UpToDate®; 2006
47. Rose BD editor. *Cyclosporin/Methotrexate*. UpToDate ed. Waltham, Massachusetts: UpToDate®; 2006
48. Hospira Healthcare Corporation. *Methotrexate Injection USP® product monograph*. Saint-Laurent, Quebec; 27 June . 2012
49. MICROMEDEX® 2.0 Drug Interactions (database on the Internet). *Methotrexate*. Thomson Reuters, updated periodically. Available at: <http://www.thomsonhc.com/micromedex2>. Accessed 31 July, 2013
50. Suzuki K, Doki K, Homma M, et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. *Br J Clin Pharmacol* 2008;67(1):44-49
51. Santucci R, Leveque D, Kemmel V, et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. *Anticancer Res* 2010;30:963-966
52. *Drug Interaction Facts [database on the Internet]*. *Methotrexate*. : Facts and Comparisons 4.0; 2006
53. eFacts. *Methotrexate*. : Facts and Comparisons; 2006
54. Accord Healthcare Inc. ACH-METHOTREXATE tablets product monograph. Kirkland, Québec; January 13, 2022
55. Apotex Inc. APO-METHOTREXATE tablets product monograph. Toronto, Ontario; June 30, 2021
56. Pharmascience Inc. pms-METHOTREXATE tablets product monograph. Montréal, Québec; May 16, 2019
57. Pfizer Canada-ULC. METHOTREXATE TABLETS product monograph. Kirkland, Québec; September 12, 2019
58. Maia M, Farah ME, Belfort RN, et al. Effects of intravitreal triamcinolone acetonide injection with and without preservative. *Br J Ophthalmol* 2007;91(9):1122-1124
59. BC Cancer Gynecology Tumour Group. (GOTDLRM) BC Cancer Protocol Summary for Therapy for Low Risk Gestational Trophoblastic Cancer using Methotrexate. Vancouver, British Columbia: BC Cancer; September 1 2022
60. Braga A, de Souza Hartung Araújo, C., Ribeiro Mora PA, et al. Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend. *Gynecol Oncol* 2020;156(3):598-605
61. Brigitte Vachon. Clinical Specialist, Pfizer/Hospira Healthcare Corporation. Personal communication. 15 December 2015
62. Dorr RT, Von-Hoff DD. *Cancer chemotherapy handbook*. 2nd ed. Norwalk, Connecticut: Appleton & Lange; 1994. p. 27-28,123
63. Rubenstein EB, Peterson DE, Schubert M, et al. *Clinical Practice Guidelines for the Prevention and Treatment of Cancer Therapy-Induced Oral and Gastrointestinal Mucositis*. Supplement to *Cancer* 2004;100(9):2026-2046
64. Bae JH, Lee SC. Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease. *Retina* 2012;32(7):1395-1402



65. Yeh S, Wilson DJ, Casey Eye Institute Portland Oregon. Correspondence: Combination intravitreal rituximab and methotrexate for massive subretinal lymphoma. *Eye* 2010;24(10):1625-1626
66. Trissel L. Handbook on injectable drugs. 13th ed. Bethesda, Maryland: American Society of Health-System Pharmacists; 2005. p. 990
67. BC Cancer Agency Head and Neck Tumour Group. (HNM) BCCA Protocol Summary for Head and Neck Cancer Using Methotrexate as Standard Therapy. Vancouver, British Columbia: BC Cancer Agency; 2005
68. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. *Ann.Oncol.* 2002;13(1):73-80
69. Gebbia V, Boussem H, Valerio MR. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma. *Anticancer Res.* 2012;32(2):529-536
70. BC Cancer Agency Breast Tumour Group. (BRAVCMPO) BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using Metronomic Low-Dose Oral Cyclophosphamide. Vancouver, British Columbia: BC Cancer Agency; 1 July 2012
71. Orlando L, Cardillo A, Rocca A, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. *Anticancer Drugs* 2006;17(8):961-967
72. Colleoni M, Orlando L, Sanna G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. *Ann.Oncol.* 2006;17(2):232-238
73. BC Cancer Agency Lymphoma Tumour Group. (LYPALL) BCCA Protocol Summary for Lymphoma Palliative Chemotherapy. Vancouver, British Columbia: BC Cancer Agency; 2005
74. BC Cancer Agency Miscellaneous Origin Tumour Group. (UMOHDMTX) BCCA Protocol Summary for Treatment of Meningeal Disease (Miscellaneous Tumour Origins) using High Dose Methotrexate with Leucovorin Rescue. Vancouver, British Columbia: BC Cancer Agency; 1999
75. BC Cancer Agency Sarcoma Tumour Group. (OSHDMTX) BCCA Protocol Summary for Treatment of Osteosarcoma Using High Dose Methotrexate with Leucovorin Rescue. Vancouver, British Columbia: BC Cancer Agency; 2000
76. BC Cancer Agency Kaposi's Sarcoma Tumour Group. (KSVB) BCCA Protocol Summary for Palliative Treatment for Kaposi's Sarcoma using Vinblastine Alternating with Vincristine. Vancouver, British Columbia: BC Cancer Agency; 2002
77. Plimack ER, Hoffman-Censits J, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. *J Clin Oncol* 2014;32(18):1895-1901
78. BC Cancer Genitourinary Tumour Group. (GUBDDMVAC) BC Cancer Protocol Summary for Neoadjuvant Treatment of Urothelial Cancer Using Dose-dense Methotrexate, vinBLASTine, DOXOrubicin and CISplatin. Vancouver, BC: BC Cancer; August 1 2022
79. BC Cancer Agency Breast Tumour Group. (BRAJCMFPO) BCCA Protocol Summary for Adjuvant Therapy of Premenopausal High Risk Breast Cancer using Cyclophosphamide (oral), Methotrexate, and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 1999
80. BC Cancer Agency Breast Tumour Group. (BRAVCMFPO) BCCA Protocol Summary for Palliative Therapy for Advanced Breast Cancer using Cyclophosphamide (oral), Methotrexate, and Fluorouracil. Vancouver, British Columbia: BC Cancer Agency; 2004
81. BC Cancer Agency Genitourinary Tumour Group. (GUMVAC) BCCA Protocol Summary for Transitional Cell Cancer of the Urothelium using Methotrexate, Vinblastine, Doxorubicin, and Cisplatin. Vancouver, British Columbia: BC Cancer Agency; 2003
82. BC Cancer Agency Miscellaneous Origin Tumour Group. (MOIT) BCCA Protocol Summary for Solid Tumours Using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine. Vancouver, British Columbia: BC Cancer Agency; 2005
83. BC Cancer Agency Lymphoma Tumour Group. (LYIT) BCCA Protocol Summary for Treatment of Lymphoma using Intrathecal Methotrexate and Cytarabine. Vancouver, British Columbia: BC Cancer Agency; 2004
84. Rose BD editor. Methotrexate. UpToDate 17.3 ed. Waltham, Massachusetts: UpToDate®; 2010
85. Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. *J Clin Oncol* 2003;21(6):1044-9
86. BC Cancer Agency Lymphoma Tumour Group. (LYHDMRP) BCCA Protocol Summary for Treatment of Primary Intracerebral Lymphoma with High Dose Methotrexate and Rituximab. Vancouver, British Columbia: BC Cancer Agency; 1 May 2009
87. Floyd J, Mirza I, Sachs B, et al. Hepatotoxicity of Chemotherapy. *Sem Onc* 2006;33(1):50-67
88. Aronoff GR, Brier ME, Berns JS, Bennett W. The Renal Drug Book 2006. Available at: <http://www.kdp-baptist.louisville.edu/renalbook/expand.asp?ID=1436>; Accessed 4 May 2006